Atlas Trials

Safety/Efficacy Study of 2nd Cycle Treatment After 6 Months of 1st Cycle HLA-haplo Matched Allogenic Bone Marrow Derived Stem Cell Treatment in ALS

Clinical trial NCT03214146 · UNKNOWN

Trial details

NCT number
NCT03214146
Sponsor
Hanyang University Seoul Hospital
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
Amyotrophic Lateral Sclerosis
Start date
2017-02-01
Primary completion
2019-03-25
Enrollment
6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.